Earnings ·
BeOne Medicines reports $1.9B Q3 revenue, raises full-year guidance to $6.9-$7.0B
BEIGFBeOne Medicines Ltd.
BeOne Medicines Ltd. reported third-quarter 2026 total revenues of $1.89 billion, a 34% increase from the prior year, driven by $1.4 billion in BRUKINSA sales and $243 million in TEVIMBRA sales. The company posted diluted GAAP earnings per ADS of $3.28 and raised its full-year 2026 total revenue guidance to $6.9-$7.0 billion, up from the previous range of $6.6-$6.8 billion. Operating income also saw significant growth, with GAAP operating income reaching $419 million for the quarter. BeOne Medicines is a global oncology company that discovers and develops innovative cancer treatments.